Eisai Plans U.S. Filing For Antibody Against Toxic Cause Of Alzheimer's
This article was originally published in PharmAsia News
Executive Summary
Eisai plans to begin clinical trials in the United States by June for its BAN2401 monoclonal antibody to kill a toxic protein associated with Alzheimer's disease